Startups
Over the past year, the world at large has become more familiar with mRNA technology. Now the world will be introduced to a new type of RNA-based medicine called eRNA.
With 2020 holding a record number of biotech IPOs, this year is lining up to come close. Three more Bay Area life science companies are just about ready to hit the Nasdaq, adding to the growing list for 2021.
Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds.
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.
April showers bring May dollars. Here’s whose cash gardens are really blooming this week in the life sciences world.
Neuroelectrics, based in Barcelona, Spain with offices in Cambridge, Massachusetts, announced it had raised $17.5 million in a Series A financing round. It was led by Morningside Ventures.
Grabbing a fast-tracked novel enzyme replacement therapy for a rare pediatric disease, new biopharma Aceragen launched with $35 million in hand for product financing.
The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.
Two months after Centessa Pharmaceuticals launched following the merger of 10 private biotech companies, the company is already eying a $100 million splash on the Nasdaq stock exchange.
PRESS RELEASES
